130.20Open130.20Pre Close0 Volume1 Open Interest140.00Strike Price0.00Turnover108.87%IV6.77%PremiumDec 20, 2024Expiry Date113.07Intrinsic Value100Multiplier20DDays to Expiry17.13Extrinsic Value100Contract SizeAmericanOptions Type0.9933Delta0.0003Gamma2.23Leverage Ratio-0.0451Theta0.0746Rho2.21Eff Leverage0.0110Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet